|
Target Audience
- The target audience for this conference is based upon a group that
would benefit from learning more about problems of high-risk pregnancy.
This would include perinatologists, general OB-GYN’s and nursing
staff involved in the care of high-risk pregnancies, both within the
office and within a hospital setting.
Accreditation
Statement:
This activity has been planned and implemented in accordance with the
Essential Areas and Policies of the Accreditation Council for Continuing
Medical Education through the joint sponsorship of the University of
California, Irvine College of Medicine and Nevada Perinatal Foundation.
The University of California, Irvine College of Medicine is accredited
by the ACCME to provide continuing medical education
for physicians.
|
Designation Statement:
The University of California, Irvine College of Medicine designates
this educational activity for a maximum of 19 category 1 credits toward
the AMA Physician’s Recognition Award. Each physician should claim
only those credits that he/she actually spent in the activity.
Disclosure:
It is the policy of the University of California, Irvine College of
Medicine that the faculty and sponsor discloses real or apparent conflict
of interest relating to the topics of this educational activity and
also discloses discussion of unlabelled/unapproved uses of drugs or
devices during their presentation(s). Detailed disclosure will be made
in writing in the activity handout materials.
|
ADA
In compliance with the Americans’ with Disabilities Act, please
notify Stephanie Aguilar at (702) 382-3200 if you have any special needs.
We will make every reasonable effort to comply with your request.
Objectives
1) Define new information on dealing with preeclampsia.
2) Identify appropriate
management of the patient with oligohydramnios.
3) Recognize the
new role of progesterone for the prevention of prematurity.
4) Define of ultrasound
modalities
and management of twin gestations, especially that of monoamniotic twin
gestations.
5) Recognize etiologies
and prevention of cerebral palsy in the antepartum period
and the new task force requirement on the documentation on the development
of intrapartum cerebral palsy.
|
6) Identify and
recognize the ethical usage and new treatment uses for umbilical cord
stem cells.
7) Recognize more
uses of information
on abnormalities via ultrasound and management, specifically of performance
and management of fetal intracranial ultrasonography.
8) Recognize rational
protocols for the patient with previable, preterm premature rupture
of membranes.
9) Identify reasons
why patients litigate against their obstetrician/gynecologist.
We wish to thank
Valley Hospital Center and The Phillips Corporation for their grant
in support of this activity.
|
